Approved by FDA for prevention of postoperative nausea and vomiting, February 2020.
Avoid use in patients with congenital long QT syndrome and in patients taking droperidol.
- TRADE NAMES: Barhemsys (Acacia Pharma); Deniban (Sanofi-Aventis); Solian (Sanofi-Aventis)
- INDICATIONS: Prevention of postoperative nausea and vomiting (lower doses). Psychoses, schizophrenia (higher doses)
- CLASS: Antiemetic, Antipsychotic, Antipsychotic, atypical, Dopamine receptor antagonist
- HALF-LIFE: 4–5 hours (following intravenous infusion)
- FDA APPROVAL DATE: 02/26/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Bepridil, Cisapride, Disopyramide, Droperidol, Erythromycin, Flecainide, Levodopa, Ondansetron, Pentamidine, Procainamide, Quinidine, Sotalol, Sparfloxacin, Terfenadine, Thioridazine - PREGNANCY: Insufficient data to establish a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 12/18/2024
